Palmitoyl derivatives of interferon α: Potential for cutaneous delivery

Journal of Pharmaceutical Sciences

Volumn 87, Issue 10, 1998, Pages 1203-1208

  Foldvari, Marianna ^a   Attah Poku, Samuel ^b   Hu, Jiaping ^a   Li, Qimin ^a   Hughes, Huw ^b   Babiuk, Lorne A ^b   Kruger, Sandra ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON DERIVATIVE; ALPHA2B INTERFERON; PALMITIC ACID DERIVATIVE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; HUMAN; HUMAN TISSUE; INTRADERMAL DRUG ADMINISTRATION; NONHUMAN; TRANSDERMAL DRUG ADMINISTRATION; VIRUS INFECTION;

EID: 0031667739     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980146k     Document Type: Article

References (27)

1. Hayakawa, E.; Chien, D. S.; Inagaki, K.; Yamamoto, A.; Wang, W. Lee, V. H. L. Conjuctival penetration of insulin and peptide drugs in the albino rabbit. Pharm. Res. 1992, 9, 769-775.
2. Richardson, J. L.; Illum, L.; Thomas, N. W. Vaginal absorption of insulin in the rat: Effect of penetration enhancers on insulin uptake and mucosal histology. Pharm. Res. 1992, 19 878-883.
3. Bodde, H. E.; Verhoef, J. C.; Ponec, M. Transdermal peptide delivery. Biochem. Soc. Trans. 1989, 1, 943-945.
4. Hoogstraate, A. J.; Verhoef, J. C.; Ijzerman, A. P.; Spies, F.; Bodde, H. E. Kinetics, ultrastructural aspects and modeling of transdermal peptide flux enhancement by N-alkylazacy-cloheptanones. Int. J. Pharm. 1991, 76, 37-47.
5. Choi, H. K.; Flynn, G. L.; Amidon, G. L. Transdermal delivery of bioactive peptides: The effect of n-decylmethyl sulfoxide, pH and inhibitors on enkephalin metabolism and transport. Pharm. Res. 1990, 7, 1099-1106.
6. Morimoto, K.; Iwakura, Y.; Miyazaki, M.; Nakatani, E. Effects of proteolytic enzyme inhibitors of enhancement of transdermal iontophoretic delivery of vasopressin and an analogue in rats. Int. J. Pharm. 1992, 81, 119-125.
7. Kumar, S.; Char, H.; Patel, S.; et al. In vivo transdermal iontophoretic delivery of growth hormone releasing factor GRF (1-44) in hairless guinea pigs. J. Controlled Release 1992, 18, 213-220.
8. Clemens, M. J. Molecular mechanism of interferon action. Br. J. Clin. Pract. 1988, 42, 5-12 1988.
9. Pestka, S.; Langer, J. A.; Zoon, K. C.; Samuel, C. E.. Interferons and their actions. Annu. Rev. Biochem. 1987, 56, 727-777.
10. Baglioni, C.; Phipps, R. J.. Nasal absorption of interferon: Enhancement by surfactant agents. J. Interferon Res. 1990, 10, 497-504.
11. Farr, B. M.; Gwaltney, J. M.; Adams, K. F.; Hayden, F. G. Intranasal interferon-α2 for prevention of natural rhinovirus colds. Antimicrob. Agents Chemother. 1984, 26, 31-34.
12. Freeman, D. J.; McKeough, M. B.; Spruance, S. L. Recombinant human interferon αA treatment of an experimental cutaneous herpes simplex virus type 1 infection of guinea pigs. J. Interferon Res. 1987, 7, 213-222.
13. Keay, S.; Teng, N.; Eisenberg, M.; Story, B.; Sellers, P. W.; Merigan, T. C. Topical interferon for treating condyloma acuminata in women. J. Infectious Dis. 1988, 158(5), 934-939.
14. Glezerman, M.; Cohen, V.; Shoham, J.; et al. Placebo-controlled trial of topical interferon in labial and genital herpes. Lancet 1988, 1, 150-152.
15. Kobrinskii, G. D.; Melnikov, V. R.; Kulakov, V. N.; Lvov, N. D.; Bolotin, I. M.; Barinskii. I. F. Treatment of experimental genital herpes with liposomal interferon. Biomed. Sci. 1991, 2, 29-32.
16. Hamuryudan, V.; Yurdakul, S.; Rosenkaimer, F.; Yazici, H. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Bechet's Syndrome: a randomized, double blind trial. Br. J. Rheumatol. 1991, 30, 395-396.
17. 125I and lactoperoxidase. Methods Enzymol. 1986, 119, 263-267.
18. Ohmann, B.; Gilchrist, J. E.; Babiuk, L. A. Effect of recombinant DNA-produced bovine IFN alpha (BoIFN-) on the interaction between bovine alveolar macrophages and bovine herpesvirus type-I. J. Gen. Virol. 1984, 65, 1485-95.
19. Wetzel, R. Assignment of the disulphide bonds of leukocyte interferon. Nature 1981, 289, 606-607.
20. Morehead, H.; Johnston, P. D.; Wetzel, R. Roles of the 29-138 disulfide bond of subtype A of human a interferon in its antiviral activity and conformational stability. Biochemistry 1984, 23, 2500-2507.
21. Bewley, T. A.; Levine, H. L.; Wetzel; R. Structural features of human leukocyte interferon A as determined by circular dichroism spectroscopy Int. J. Pept. Protein Res. 1982, 20, 93-96.
22. Fish, E. N.; Banerjee, K.; Stebbing, N. The role of three domains in the biological activity of human interferon-α. J. Interferon Res. 1989, 9, 97-114.
23. Korn, A. P.; Rose, D. R.; Fish, E. N. Three-dimensional model of a human interferon-α consensus sequence. J. Interferon Res. 1994, 14, 1-9.
24. Hashimoto, M.; Takada, K.; Kiso, Y.; Muranishi, S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm. Res. 1989, 6, 171-176.
25. Baron, S.; Tyring, S. K.; Fleishman, Jr., W. R.; Coppenhaver, D. H.; Niesel, D. W.; Klimpel, G. R.; Stanton, G. J,; Hughes, T. K. Interferons: Mechanisms of action and clinical applications. JAMA 1991, 266, 1375-1383.
26. Weiner, N.; Williams, N.; Birch, G.; Ramachandran, C. Shipman, Jr., C.; Flynn, G. Topical delivery of liposomaly encapsulated interferon evaluated in a cutaneous Herpes guinea pig model. Antimicr. Agents Chemother. 1989, 33, 1217-1221.
27. Foldvari, M.; Moreland, A. Clinical Observations with topical liposome-encapsulated interferon alpha for the treatment of genital papillomavirus infections. J. Liposome Res. 1997, 7, 115-126.